BAX 817
Baxter’s haemophilia drug performs
March 17, 2015Sales and Marketing BAX 817, VIIa, baxter, haemophilia, rFVIIa
Baxter International has reported positive Phase III clinical trial results for its investigational haemophilia drug BAX 817. The recombinant factor VIIa …
Latest content
EnteroBiotix appoints former GSK Chief Medical Officer to board
November 3, 2026
AI: an early warning system for patient safety
November 3, 2026
Highlighting the value of lab research for healthcare innovation
November 2, 2026
